Pharvaris (PHVS) AI Stock Analysis

• Market Cap: $1.78B
• Dividend Yield: N/A
• Average Volume (3M): 202.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: N/A
• EPS Growth: -20.08%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.71
• Shares Outstanding: 64,055,640
• 10 Day Avg. Volume: 143,115
• 30 Day Avg. Volume: 202,303
• PEG Ratio: 1.31
• Price to Book (P/B): 3.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.29
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -11.89K
• Enterprise Value/Ebitda: -7.43
• 1Y Price Target: $41.00
• Price Target Upside: 47.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $27.00 ▼(-2.84% Downside)

The score reflects high fundamental risk from being pre-revenue with widening losses and heavy negative free cash flow, partly offset by a low-debt balance sheet and solid equity base. Technically, price action is supportive (trading above key moving averages with neutral-to-positive momentum), while valuation is constrained by negative earnings and no dividend data.

Positive Factors

Strong Equity Position

A strong equity position provides financial stability and reduces reliance on debt, which is crucial for a clinical-stage company navigating through development phases.

Proprietary Platform

The proprietary platform can lead to innovative treatments, offering a competitive edge in the biotechnology sector and potential for future revenue streams.

Financing Activities

Strong financing activities ensure liquidity, enabling continued R&D investment and operational stability while advancing drug candidates through trials.

Negative Factors

No Revenue Generation

The absence of revenue generation poses significant risks to long-term sustainability, as the company relies on external funding to support operations and development.

Negative Cash Flow

Persistent negative cash flow indicates ongoing cash burn, which can strain financial resources and limit the company's ability to fund future growth initiatives.

Ongoing Losses

Continuous losses highlight challenges in achieving profitability, which is critical for long-term viability and attracting future investment in the biotech industry.

Pharvaris Business Overview & Revenue Model

Company Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

How the Company Makes Money

Pharvaris makes money by developing and commercializing oral therapies, primarily focusing on hereditary angioedema (HAE). As a clinical-stage company, its revenue model is dependent on advancing its drug candidates through clinical trials and eventually obtaining regulatory approval for commercial sale. Revenue streams are expected to come from potential future sales of approved therapies, licensing agreements, and partnerships with other pharmaceutical companies. Significant partnerships could involve collaboration on research and development, co-marketing, or distribution agreements that enhance the company's ability to bring its therapies to market.

Pharvaris Financial Statement Overview

Summary

Financials are mixed: the company is pre-revenue with widening losses (TTM net loss ~$166M vs. ~$134M in 2024) and deeply negative operating/free cash flow (both ~-$134M TTM), indicating elevated and potentially rising burn. Offsetting this, leverage is minimal (~$0.6M debt; near-zero debt-to-equity) and equity remains sizable (~$312M), supporting solvency and funding flexibility.

Income Statement

PHVS is still pre-revenue (revenue is $0 in both TTM (Trailing-Twelve-Months) and all annual periods provided), so profitability is entirely driven by operating spend. Losses have widened materially in TTM (Trailing-Twelve-Months) (net loss of about $166M vs. ~$134M in 2024), indicating a rising burn profile. A key positive is that losses are typical for a clinical-stage biotech, but the lack of revenue and worsening net results keep income statement quality weak.

Balance Sheet

The balance sheet is a relative strength: leverage is minimal (TTM total debt ~0.6M and debt-to-equity near zero), which reduces financial risk and interest burden. Equity remains sizable (~$312M TTM), supporting funding flexibility. The main weakness is ongoing negative returns on equity (TTM return on equity roughly -69%), reflecting heavy losses and a shrinking economic base if losses persist.

Cash Flow

Cash generation is weak and deteriorating: operating cash flow and free cash flow are deeply negative in TTM (Trailing-Twelve-Months) (both around -$134M), and free cash flow growth is sharply negative in TTM, signaling an accelerating cash burn. A modest positive is that free cash flow broadly tracks net loss (free cash flow to net income ~1x), suggesting the losses are not being materially understated by non-cash accounting—however, the absolute burn level remains the core risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-97.02K	0.00	0.00	0.00	0.00	―
EBITDA	-155.20M	-145.59M	-96.66M	-86.56M	-54.06M	-29.71M
Net Income	-166.04M	-134.22M	-100.88M	-76.33M	-42.73M	-29.62M
Balance Sheet
Total Assets	338.90M	291.37M	398.69M	167.73M	212.09M	101.10M
Cash, Cash Equivalents and Short-Term Investments	329.29M	280.73M	391.23M	161.84M	209.35M	98.63M
Total Debt	578.66K	861.47K	238.91K	436.82K	250.18K	0.00
Total Liabilities	26.66M	23.61M	14.65M	18.47M	7.14M	5.31M
Stockholders Equity	312.24M	267.76M	384.05M	149.26M	204.95M	95.79M
Cash Flow
Free Cash Flow	-134.40M	-120.67M	-93.14M	-67.29M	-44.73M	-21.54M
Operating Cash Flow	-134.07M	-120.13M	-93.05M	-67.16M	-44.60M	-21.50M
Investing Cash Flow	-324.00K	-538.09K	-89.98K	-124.30K	-130.03K	-42.98K
Financing Cash Flow	160.90M	2.68M	325.39M	8.65M	143.67M	101.20M

Pharvaris Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 27.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Positive. The current price of 27.79 is above the 20-day moving average (MA) of 26.38, above the 50-day MA of 25.82, and above the 200-day MA of 21.70, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 58.99 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHVS.

Pharvaris Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	60 Neutral	$3.21B	-9.50	-47.40%	―	23340.07%	18.06%
PHVS	56 Neutral	$1.78B	-8.64	-51.81%	―	―	-20.08%
EWTX	55 Neutral	$3.04B	-18.25	-30.02%	―	―	-5.73%
CLDX	53 Neutral	$1.65B	-7.30	-32.44%	―	-73.94%	-31.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCRX	51 Neutral	$1.65B	-141.01	―	―	45.38%	92.85%
BHVN	48 Neutral	$1.77B	―	-522.08%	―	―	18.76%

Pharvaris Corporate Events

Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts

On January 12, 2026, Pharvaris outlined its 2026 strategic priorities centered on advancing deucrictibant through late-stage development and toward commercialization in hereditary and acquired angioedema. Following the December readout of its pivotal Phase 3 RAPIDe-3 study, which met primary and secondary endpoints for on-demand HAE treatment, the company is preparing a U.S. New Drug Application for deucrictibant in the first half of 2026, with additional marketing applications to follow, and is progressing multiple Phase 3 programs, including CHAPTER-3 for long-term HAE prophylaxis and the CREAATE trial in AAE-C1INH. Pharvaris is also extending its clinical dataset with the long-term CHAPTER-1 results, which showed sustained reductions in HAE attack rates over roughly three years, and is running the CHAPTER-4 extension to further assess long-term safety and effectiveness. Management highlighted an estimated cash runway into the first half of 2027 and recent inclusion in the Nasdaq Biotechnology Index, reinforcing the company’s financial and market positioning as it moves toward potential launch of deucrictibant and expands its visibility through upcoming investor conferences and medical congress presentations.

The most recent analyst rating on (PHVS) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.

Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment

On December 3, 2025, Pharvaris announced positive topline data from its RAPIDe-3 pivotal study, highlighting the potential of deucrictibant for on-demand treatment of HAE attacks. The study demonstrated that deucrictibant met its primary and all secondary endpoints, showing faster symptom relief and a well-tolerated safety profile compared to placebo. These results are expected to support marketing authorization applications in 2026, potentially positioning deucrictibant as a significant treatment option for HAE, offering both on-demand and prophylactic control of angioedema attacks.

The most recent analyst rating on (PHVS) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.

Pharvaris Reports Q3 2025 Financial Results and Business Progress

On November 12, 2025, Pharvaris reported its financial results for the third quarter of 2025 and provided updates on its business operations. The company highlighted the progress of its pivotal Phase 3 studies, including RAPIDe-3 and CHAPTER-3, which are evaluating deucrictibant for the treatment and prevention of HAE attacks. Pharvaris also initiated the CREAATE study for AAE-C1INH attacks. The company maintains a strong financial position with €329 million in cash and cash equivalents, and it successfully closed a $201 million public offering to extend its cash runway into the first half of 2027. These developments underscore Pharvaris’ commitment to advancing its pipeline and enhancing its market positioning in the treatment of bradykinin-mediated diseases.

The most recent analyst rating on (PHVS) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.